


Please type a plus sign (+) inside this box →




PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|--|---|------------------------|-------------------|
| Substitute for form 1449A/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary) | | Application Number | 09/709,045 |
| | | Filing Date | November 10, 2000 |
| | | First Named Inventor | M. Rigdon Lentz |
| | | Group Art Unit | 1647 |
| | | Examiner Name | J. Seharaseyon |
| | | Attorney Docket Number | LEN 102 |
| Sheet | 2 | of | 2 |

| OTHER ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| JS | | ADERKA, et al., "Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients," <i>Cancer Res.</i> 51: 5602-5607 (1991). | |
| | | AMIT, et al., "Three-dimensional structure of an antigen-antibody complex at 2.8 resolution," <i>Science</i> 233: 747-751 (1986). | |
| | | DIGEL, et al., "High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia," <i>J. Clin. Invest</i> 89: 1690-1693 (1992). | |
| | | ELSÄSSER-BEILE, et al., "Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients," <i>Tumor Biol.</i> 15: 17-24 (1993). | |
| | | KESSLER, "Adsorptive plasma treatment: optimization of extracorporeal devices and systems," <i>Blood Purif.</i> 11: 150-157 (1993). | |
| | | LENTZ, et al., "Low molecular weight protein apheresis and regression of breast cancer," <i>Jpn. J. Apheresis</i> 16(1): 107-114 (1997). | |
| | | PANKA, et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 85: 3080-3084 (1988). | |
| | | RUDIHOFF, et al., "Single amino acid substitution altering antigen-binding specificity," <i>Immunology</i> 79: 1979-1983 (1982). | |
| | | SELINSKY & HOWELL, "Soluble tumor necrosis factor receptor type I enhances tumor development and persistence <i>in vivo</i> ," <i>Cell. Immunol.</i> 200: 81-87 (2000). | |
| | | SELINSKY, "Dissertation: The role of soluble tumor necrosis factor type I in tumor survival," Colorado State University, Fort Collins, Colorado (1999). | |

| | | | |
|----------------------|---|-----------------|--------|
| Examiner's Signature |  | Date Considered | 2/4/04 |
|----------------------|---|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+